Last reviewed · How we verify
NCT04678739
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Phase 3 trial testing Remdesivir in Covid19 in 205 participants. Completed in 10 February 2021.
30 January 2021
Quick facts
| Lead sponsor | M Abdur Rahim Medical College and Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 205 |
| Start date | 15 August 2020 |
| Primary completion | 30 January 2021 |
| Estimated completion | 10 February 2021 |
| Sites | 4 locations across Bangladesh |
Drugs / interventions tested
- Remdesivir (remdesivir) — full drug profile →
- Tocilizumab (tocilizumab) — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
- Covid-19 ARDS — all drugs for Covid-19 ARDS →
Sponsor
M Abdur Rahim Medical College and Hospital
Who can join
Adults 16 to 80, any sex, with Covid19 or Covid-19 ARDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
Remdesivir for the treatment of COVID-19.
Ansems K, Grundeis F, Dahms K, Mikolajewska A, et al · · 2021 · cited 89× · PMID 34350582 · DOI 10.1002/14651858.cd014962 -
Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049 -
Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, et al · · 2023 · cited 55× · PMID 36695483 · DOI 10.1002/14651858.cd014962.pub2 -
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Zizzo G, Tamburello A, Castelnovo L, Laria A, et al · · 2022 · cited 55× · PMID 35340805 · DOI 10.3389/fimmu.2022.795315 -
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761 -
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.
Zhang S, Asquith B, Szydlo R, Tregoning JS, et al · · 2021 · cited 31× · PMID 35965490 · DOI 10.1093/immadv/ltab015 -
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, et al · · 2021 · cited 26× · PMID 34064039 · DOI 10.3390/ijms22115438
Verify or expand the search:
- PubMed search for NCT04678739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remdesivir
Trials testing the same drug.
- NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
- NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
- NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
- NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
- NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other M Abdur Rahim Medical College and Hospital trials
Trials by the same sponsor.
- NCT04693026 — Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04678739 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M Abdur Rahim Medical College and Hospital
- Last refreshed: 2 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04678739.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing